Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS...
-
Upload
ryan-mccallum -
Category
Documents
-
view
217 -
download
3
Transcript of Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS...
![Page 1: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/1.jpg)
Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics
Nathan Clark, Pharm D, BCPS
Clinical Pharmacy Supervisor
Anticoagulation and Anemia Services
Kaiser Permanent Colorado
![Page 2: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/2.jpg)
Objectives
• Review recommendations from ACCP regarding INR monitoring intervals
• Discuss the consequences of non-adherence with INR monitoring
• Review recommendations from ACCP regarding the management of first episode, near-miss INR
• Discuss the risk of thromboembolism among stable patients presenting with a significantly low INR
![Page 3: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/3.jpg)
Survey:
What is the maximum duration between INR checks at your institution for stable warfarin patients?
a. 4 weeks
b. 8 weeks
c. 12 weeks
d. Something else?
![Page 4: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/4.jpg)
Frequency of INR Monitoring
“…VKA therapy with consistently stable INRs, we suggest INR testing up to every 12 weeks rather than every 4 weeks” (Grade 2B)
CHEST 2012; 141(2)(Suppl):e152S–e184S
![Page 5: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/5.jpg)
Frequency of INR Monitoring
Frequency of INR testing has evolved from expert opinion
Data regarding extended INR recall intervals is conflicting
![Page 6: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/6.jpg)
4 weeks versus 12 weeks
250 patients were randomized to either 4 week or 12 week recheck INR intervals
• Target INR 2–3 or 2.5–3.5• No dose change in previous 6 months
Primary outcome was TTR
Ann Intern Med. 2011;155:653-659
![Page 7: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/7.jpg)
4 weeks versus 12 weeks
Outcome 4 week (n=126)
12 week(n=124)
TTR % (SD %) 74.1 (18.8) 71.6 (20.0)1
≥ 1 dose changes; n (%) 70 (55.6) 46 (37.1)2
INR ≥ 4.5; n (%) 15 (11.9) 8 (6.5)
INR ≤ 1.5; n (%) 12 (9.5) 11 (8.9)
Clinical Events; n (%) Major bleeding 1 (0.8) 2 (1.6)
Thromboembolism 1 (0.8) 0 (0)
Death 5 (4.0) 2 (1.6)TTR – time in therapeutic range; SD – standard deviation; INR – international normalized ratio1-Noninferiority established, absolute difference = 2.5% (1 sided 97.5% CI upper bound 7.3%)2- Absolute difference = 18.5% (6.1 to 30.0); p=0.004
![Page 8: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/8.jpg)
Survey:
How much staff time is spent reminding patients to come in for repeat INR testing each week at your center?
a. Less than one hour
b. 1 to 5 hours
c. More than 5 hours
d. No idea, but more time than I care to think about
![Page 9: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/9.jpg)
Nonadherence
Most studies of adherence have evaluated pill taking behavior•Less reliable pill taking = poor INR control
ART-DECO study evaluated adherence with lab monitoring•Less reliable INR monitoring = greater risk of TE
Arch Intern Med 2007 Feb 12;167(3):229-35
![Page 10: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/10.jpg)
Improving Adherence with INR Monitoring
Interactive voice response (IVR) calls
Study evaluated IVR to provide INR results, warfarin dose details and recheck INR plus reminders
• No change in INR control • 80.3% vs 79.9%
• Reduced workload
CMAJ 2009 Apr 28;180(9):927-33
![Page 11: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/11.jpg)
Improving Adherence with INR Monitoring
Down side to IVR?• Many patients don’t like the calls (some
strongly dislike them)• Elderly patients are often unable to
interact or operate IVR• 1 in 5 patients older than 65 were unable
perform any IVR task
J Gerontol B Psychol Sci Soc Sci 2012 Oct 25. [Epub ahead of print]
![Page 12: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/12.jpg)
Improving Adherence with Pill Taking
Lottery-based incentive program RCT
Lottery arm:• 1 in 5 chance of getting $10 each day• 1 in 100 chance of getting $100 each day
Control arm:• No incentive
Am Heart J 2012;164:268-74
![Page 13: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/13.jpg)
Improving Adherence with Pill Taking
Overall, no change in out of range INRs:• 23.0% lottery vs 25.9% control; p>0.05
In-range INR at study entry:• No change in out of range INRs: OR=1.26
(95% CI, 0.76-2.09, p=0.37)
Low INR at study entry:• Reduction in out of range INRs; OR=0.39
(95% CI, 0.25-0.62, p<0.001)
Am Heart J 2012;164:268-74
![Page 14: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/14.jpg)
Case 1
C.Y. is a 76 yoF with AF and HTN. No other notable risk factors for stroke or bleeding. Her warfarin dose has been stable for months with therapeutic INR control. Today she presents with an INR of 1.7 (target 2-3). There are no identifiable causes for the low INR.
![Page 15: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/15.jpg)
Survey:
Which do you recommend?
a.Increase weekly warfarin dose 10%
b.Increase weekly warfarin dose 15% and start LMWH bridge
c.No change in warfarin dose
d.Follow DAWN AC suggestion
e.Something else?
![Page 16: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/16.jpg)
Isolated out-of-range INRs
“…previously stable therapeutic INRs who present with a single out-of-range INR of ≤0.5 below or above, we suggest continuing the current dose…” (Grade 2C)
CHEST 2012 141(2)(Suppl):e152S–e184S
![Page 17: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/17.jpg)
Survey:
When would you recheck the INR for C.Y.?
a. 1 week
b. 2 weeks
c. 4 weeks
d. Follow DAWN AC suggestion
e. Something else?
![Page 18: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/18.jpg)
Isolated out-of-range INRs
“…single out-of-range INR of ≤0.5 below or above, we suggest continuing the current dose and testing the INR within 1 to 2 weeks” (Grade 2C)
CHEST 2012; 141(2)(Suppl):e152S–e184S
![Page 19: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/19.jpg)
Low INRs
Over 2 years of follow up, 1 in 3 patients will have an INR ≤ 1.5
Causes of subtherapeutic INR include: Nonadherence (17%) Invasive procedures (16%) Dose reduction (15%) Unexplained (15%) Second or greater consecutive low INR (13%)
Circ Cardiovasc Qual Outcomes 2009; 2: 591-597
![Page 20: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/20.jpg)
Low INR: Risk of Thromboembolism
Retrospective cohort studies have attempted to isolate and quantify the risk of significantly low INR values
INR ≥ target range
INR ≥ target range
INR ≥ 0.5 below target
range90 day follow up for TE
≥ 2 weeks
≥ 2 weeks
![Page 21: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/21.jpg)
Low INR: Risk of Thromboembolism
Anticoagulation characteristics were comparable:•Therapeutic doses of LMWH for bridging were uncommon (1.2 to 3.2%)•Median index INR 1.4 to 1.75•Mean duration of subtherapeutic anticoagulation ~ 16 days (2 studies)
1. Am J Hematol 2012; 87:384–3872. J Thorac Cardiovasc Surg 2009;137:91-33. Pharmacotherapy 2008;28(8):960–967
![Page 22: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/22.jpg)
Low INR: Risk of Thromboembolism
Indication for VKA (n)
1 2 3
![Page 23: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/23.jpg)
Influence of LMWH Bridge Therapy
Dentali [2] described LMWH bridging in 12.8% (64 of 501 patients)• Prophylactic dose (n=11, 2.2%)• Intermediate dose (n=37, 7.4%)• Therapeutic dose (n=16, 3.2%)
• Baseline characteristics did not differ between those who did or did not receive LMWH bridging
Am. J. Hematol 2012; 87:384–387
![Page 24: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/24.jpg)
Low INR: Risk of Thromboembolism
Am. J. Hematol 2012; 87:384–387
MVR or AF patients
![Page 25: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/25.jpg)
The Low INR Study: Case-Control Design
INR ≥ target range
Index INR ≤ 0.5 below target range
Index INR within target INR range
90 day follow up: No INR criteria
90 day follow up: No INR ≥ 0.2 below target
Low INR Cohort
Therapeutic Cohort
≥ 2 weeks ≥ 2 weeks
![Page 26: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/26.jpg)
The Low INR Study
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
Thromboembolism Bleeding AC-Related Death
% a
t 90
day
s
Low INR Study Outcomes (n=2597)
Low INR Control *p>0.05 for all comparisons
Pharmacotherapy 2008;28(8):960–967
![Page 27: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/27.jpg)
Thromboembolic Outcomes
Thromboembolic events(3 studies) (n,%)• Stroke, SE, or valve thrombosis (7, 58%)• Transient ischemic attack (4, 33%)• Myocardial infarction (1, 8%)
1. Am J Hematol 2012; 87:384–3872. J Thorac Cardiovasc Surg 2009;137:91-33. Pharmacotherapy 2008;28(8):960–967
![Page 28: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/28.jpg)
Low INRs
“For patients with stable therapeutic INRs presenting with a single subtherapeutic INR value, we suggest against routinely administering bridging with heparin” (Grade 2C)
CHEST 2012; 141(2)(Suppl):e152S–e184S
![Page 29: Frequency of Monitoring, Non-adherence, and Other Anticoagulation Topics Nathan Clark, Pharm D, BCPS Clinical Pharmacy Supervisor Anticoagulation and Anemia.](https://reader035.fdocuments.in/reader035/viewer/2022081602/551444125503462d4e8b4aaf/html5/thumbnails/29.jpg)